Conditions: Psoriasis
Keywords: Moderate to severe chronic plaque psoriasis anti TNF α CDP 870 Cimzia® certolizumab pegol retreatment
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 71
Healthy volunteers: no

Brief summary:
The primary objective is to assess differences in PASI scores between Week 12 of Study C87040 \[NCT00245765\] and Week 12 of re-treatment in this study.

Detailed description:

Arms:
arm 1: Subcutaneous injections of 400 mg initial dose at Week 0 with 200 mg every 2 weeks thereafter. arm 2: Subcutaneous injections of 400 mg every 2 weeks.

Interventions: intervention 1: Certolizumab Pegol (Cimzia®)
Intervention descriptions: intervention 1: * Pharmaceutical Form: Solution for injection in pre-filled syringe
* Route of Administration: Subcutaneous use
* Dose and Administration details :

  2 x 1 mL Certolizumab Pegol at Week 0, followed by
* 1 x 1 mL Certolizumab Pegol plus 1 x 1 mL Placebo (for blinding reasons) in the Certolizumab Pegol 200 mg arm at Weeks 2, 4, 6, 8 and 10
* 2 x 1 mL Certolizumab Pegol in the Certolizumab Pegol 400 mg arm at Weeks 2, 4, 6, 8 and 10

Protocol document: